ImmuCell Corporation (ICCC)

NASDAQ: ICCC · USD

$10.6

+0.38 (+3.8%)· Recorded snapshot

Market cap	96.7M
Revenue (ttm)	30.7M
Net income (ttm)	787.4K
EPS (ttm)	$0.07
Shares out	9.1M
P/E (trailing)	142.7x
Volume	669
Beta	0.57

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 30.7M
Net income (ttm): 787.4K
EPS (ttm): $0.07
P/E (trailing): 142.7x
Market cap: 96.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E142.7

P25 n/aP50 n/aP75 n/a

ROE2.6

P25 n/aP50 n/aP75 n/a

ROIC12.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ICCC indicators

Market & fundamental data

Available fields

251

Groups with data

Currency

USD

Showing 251 of 251 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000811641
Company name	ImmuCell Corporation
Country	United States
Country code	US
CUSIP number	452525306
Earnings date	2026-11-12
Earnings time	amc
Employees	73
Employees change	-2
Employees growth	-2.67%
Enterprise value	$100.3M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1982
Industry	Biotechnology
IPO date	1987-04-30
Is primary listing	Yes
Is SPAC	No
ISIN number	US4525253062
Last 10-K release date	2026-03-30
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$96.7M
Market cap category	Micro-Cap
Next earnings date	2026-11-12
Options	No
Price	$10.65
Price currency	USD
Sector	Healthcare
SIC code	2835
Stock price date	2026-10-28
Symbol	ICCC
U.S. state	Maine
Website	https://immucell.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	0.7%
EV/Earnings	122.9x
EV/EBIT	20.74x
EV/EBITDA	13.73x
EV/FCF	22.96x
EV/Sales	3.15x
FCF / EV yield	4.36%
FCF yield	4.52%
Graham number	2.40752
Graham upside	-76.53%
P/(FCF - SBC) ratio	25.46x
P/(OCF - SBC) ratio	17.46x
P/B ratio	2.97x
P/E ratio	142.75x
P/FCF ratio	22.11x
P/OCF ratio	15.82x
P/S ratio	3.04x
Price / tangible book value	2.98x
Price/EBITDA ratio	13.22x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	15.21%
EBITDA margin	22.98%
Effective tax rate	7.76%
FCF margin	13.74%
Gross margin	40.32%
Operating margin	15.21%
Pretax margin	2.78%
Profit margin	2.57%
Profit per employee	$10,786
Profitable quarters	2
Revenue per employee	$420,213
ROA	6.25%
ROA (5Y)	-1.64%
ROCE	11.06%
ROE	2.57%
ROE (5Y)	-8.21%
ROIC	12.29%
ROIC (5Y)	-3.03%
SBC / revenue	1.81%
Tax / revenue	0.22%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-62.84%
EPS growth (Q)	259.9%
EPS growth (QoQ)	-4.76%
EPS growth 10Y	-12.95%
EPS growth quarters	2
EPS growth years	2
FCF growth	138.91%
FCF growth (Q)	57.99%
FCF growth (QoQ)	-32.71%
Gross profit growth	16.82%
Gross profit growth (Q)	-13.51%
Gross profit growth 3Y	37.36%
Gross profit growth 5Y	11.99%
Net income growth	-55.31%
Net income growth (Q)	265.56%
Net income growth (QoQ)	-5.51%
Net income growth quarters	2
Net income growth years	2
OCF growth	132.62%
OCF growth (Q)	88.52%
OCF growth (QoQ)	-15.5%
OCF growth 10Y	14.3%
Operating income growth	169.16%
Operating income growth (Q)	239.72%
Revenue growth	8.49%
Revenue growth (Q)	11.5%
Revenue growth (QoQ)	-30.62%
Revenue growth 10Y	11.29%
Revenue growth 3Y	25.05%
Revenue growth 5Y	13.74%
Revenue growth quarters	2
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.7M
Depreciation and amortization	$2.4M
EBIT	$4.7M
EBITDA	$7.1M
EPS	$0.07
FCF per share	$0.46
Financing cash flow	$-1.4M
Free cash flow	$4.2M
Free cash flow minus SBC	$3.7M
Gross profit	$12.4M
Income taxes	$66,233
Investing cash flow	$-1.7M
Net borrowing	$-1.5M
Net cash flow	$2.9M
Net income	$787,373
Operating cash flow minus SBC	$5.3M
Operating income	$4.7M
Revenue	$30.7M
Stock-based compensation	$554,758

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.51
Book value per share	$3.45
Debt / EBITDA	1.66
Debt / equity	0.4
Debt / FCF	2.95
Goodwill	$95,557
Interest coverage	10.7
Long-term assets	$25.5M
Long-term liabilities	$10.8M
Net cash (debt)	$-3.6M
Net cash / market cap	-3.85%
Net debt / EBITDA	0.51
Net debt / equity	0.11
Net debt / FCF	0.85
Piotroski F-Score	8
Property, plant and equipment	$25.4M
Shareholders' equity	$31.4M
Tangible book value	$31.3M
Tangible book value per share	$3.44
Total assets	$46.6M
Total cash	$8.9M
Total debt	$12.4M
Total liabilities	$15.3M
WACC	6.91%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.66
Current assets	$21.1M
Current liabilities	$4.4M
Current ratio	4.75
Inventory turnover	2.11
Net working capital	$9.4M
Quick ratio	2.65
Working capital	$16.6M
Working capital turnover	2.09

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-3.49%
Dividend yield	0%
Shareholder yield	-3.49%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	91.83%
10Y return CAGR	6.73%
10Y total return	91.83%
150-day SMA	$9.63
15Y price change	91.15%
15Y return CAGR	4.41%
15Y total return	91.15%
1D price change	3.75%
1M price change	8.82%
1M total return	8.82%
1W price change	3.35%
1W total return	3.35%
1Y price change	73.08%
1Y return CAGR	73.14%
1Y total return	73.08%
20-day SMA	$10.21
200-day SMA	$8.83
20Y price change	107.69%
20Y return CAGR	3.72%
20Y total return	107.69%
3M price change	-2.96%
3M total return	-2.96%
3Y price change	126.89%
3Y return CAGR	31.4%
3Y total return	126.9%
50-day SMA	$10.04
50-day SMA vs 200-day SMA	50over200
52-week high	$12.10
52-week high date	2026-07-14
52-week low	$4.52
52-week low date	2025-11-21
5Y price change	21.49%
5Y return CAGR	3.97%
5Y total return	21.49%
6M price change	30.91%
6M total return	30.91%
All-time high	$13.20
All-time high date	2021-01-29
All-time low	$1.00
All-time low date	1992-05-01
Average true range (ATR)	$0.29
Average volume	9.8K
Beta (1Y)	0.84
Beta (2Y)	-0.01
Beta (5Y)	0.57
Change from 52-week high	-12.02%
Change from 52-week low	135.51%
Change from all-time high	-18.18%
Change from all-time low	980%
Change from open	2.55%
Day's gap	1.17%
Dollar volume	$7,122
High price	$10.67
Low price	$10.29
Monthly RSI	67.44
Open price	$10.38
Position in 52-week range	93.42%
Previous close	$10.26
Price vs 150-day SMA	12.11%
Price vs 20-day SMA	5.76%
Price vs 200-day SMA	22.37%
Price vs 50-day SMA	7.62%
Relative volume	0.07
RSI	62.19
Sharpe ratio	1.26
Sharpe ratio (3Y)	0.68
Sharpe ratio (5Y)	0.25
Sortino ratio	2.13
Sortino ratio (3Y)	1.17
Sortino ratio (5Y)	0.5
Volume	669
Weekly RSI	63.36
YTD price change	75.61%
YTD total return	75.61%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	6M
Float percentage	66.42%
Shares change (QoQ)	1.58%
Shares change (YoY)	3.49%
Shares held by insiders	28.05%
Shares held by institutions	18.74%
Shares outstanding	9.1M
Short % of float	0.37%
Short % of shares	0.24%
Short ratio	1.7 days

Deeper analysis on ICCC

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ICCC report

Is a complete ICCC research report available?

No complete published report is available for ImmuCell Corporation (ICCC) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ImmuCell Corporation (ICCC)

Price

Financial snapshot

Fair-value bridge

Latest news · ICCC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ICCC indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ICCC

Frequently asked questions